LEXICON PHARMACEUTICALS INC (LXRX)
Health Care · Biotechnology · NASDAQ
Lexicon Pharmaceuticals is a biopharmaceutical company leveraging proprietary gene-knockout technology to discover and develop small molecule drugs for significant unmet medical needs.
What LEXICON PHARMACEUTICALS INC does
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drug candidates. The company utilizes a proprietary gene knockout technology to identify and validate targets for therapeutic intervention, primarily targeting areas of significant unmet medical need. Its business model relies on both direct commercialization of proprietary products and strategic licensing agreements.
Themes: drug discovery, biotechnology, gene-based therapeutic targets, R&D-stage biopharma
Fundamentals
- Price$1.76 as of 2026-10-08 close
- Market cap$783M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+23.1% 2025-10-08 close $1.43 → 2026-10-08 close $1.76
- P/En/a negative earnings
- Net margin-101.1% FY2025, SEC XBRL
- ROE-46.8% FY2025, SEC XBRL
- Debt / equity0.24 as of 2026-09-03
- Revenue growth (YoY)+123.1% as of 2026-09-03
- Revenue CAGR (3y)+610.3% SEC XBRL
- Beta1.01 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LXRX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LEXICON PHARMACEUTICALS INC looks technically
LEXICON PHARMACEUTICALS INC (LXRX) is trading 4.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 300 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago. It is 34.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.6% below its 200-day average, the long-term trend line — a long-term downtrend | -4.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.16 | $2.16 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.85 | $1.85 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 1.89. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 300 trading days ago — a "golden cross", a bullish long-term signal | 300 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control | 33.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 33.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($1.70 to $2.19) — its "stochastic" reading is 13 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.68 | $2.68 |
|---|---|---|
| From the 52-week high | it is 34.3% below its 52-week high (its highest price of the past year) | -34.3% |
| Above the 52-week low | it is 60.0% above its 52-week low (its lowest price of the past year) | +60.0% |
| Below the 52-week high | it is 34.3% below its highest point of the past year | 34.3% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $45.45 (set on 2005-07-18) | $45.45 |
| Given back of the 52-week move | over the past year its closes ranged ($1.14 to $2.64), and it has given back a bit over half of its rise from last year’s low — 59% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.67 to $1.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 58.7% |
| From the all-time high | it is 96.1% below its all-time high | -96.1% |
| Nearest price level | it is trading 1.5% below a resistance level at $1.79 — a price it turned at three times since 2026-03-13, most recently on 2026-09-25. Since 2024-10-08 it has 11 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.5% |
| All-time low | its lowest closing price on record is $0.2836 (set on 2025-03-03) | $0.2836 |
| Above the all-time low | it is 520.6% above its all-time low | +520.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1077 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1077 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.67 and $2.17 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.67 – $1.92 – $2.17 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (4.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.10× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 17.9% since the prior reading | +17.9% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Gap filled | a 4.4% gap up opened on 2026-09-28 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 7 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.1 percentage points (the stock lost 21.1% while the market gained 1.0%) | -22.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 26.3 percentage points (the stock lost 22.5% while the market gained 3.8%) | -26.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 6.8 percentage points (the stock gained 10.7% while the market gained 17.5%) | -6.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 8.1 percentage points (the stock gained 23.1% while the market gained 15.0%) | +8.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.3% of the share price. | -22.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.93 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -9.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.11 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -16.8% |
Price levels it has turned at before
LXRX last closed at $1.76 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.79 | Resistance | 1.5% above the last close | turned there three times · 2026-03-13 to 2026-09-25 |
| $1.65 | Support | 6.3% below the last close | turned there twice · 2025-10-10 to 2025-11-12 |
| $1.96 | Resistance | 11.1% above the last close | turned there twice · 2026-04-17 to 2026-08-06 |
| $1.52 | Support | 13.8% below the last close | turned there twice · 2026-03-20 to 2026-05-07 |
| $1.49 | Support | 15.6% below the last close | turned there twice · 2025-12-08 to 2026-03-30 |
| $2.04 | Resistance | 15.8% above the last close | turned there twice · 2026-05-19 to 2026-07-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $1.89.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $1.87 and $1.89 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently RAISED · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.83 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$4.55 range $2.00 – $8.00; median $4.55
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LXRX
- Consensus EPS estimate-$0.0529 next reporting period, as of 2026-10-03
- Estimate change, 30 days$0.00 from -$0.0529, on 2026-08-29, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of recurring net losses and accumulated deficit.","Substantial reliance on licensing and milestone revenue which may be irregular or non-recurring.","Significant risks associated with drug discovery, clinical development, and regulatory approval processes."]
What changed in the latest 10-Q
AI-assisted comparison of LXRX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added language that FDA provided feedback that a third-party-funded, investigator-initiated study of sotagliflozin appears adequate to provide viable evidence on DKA incidence and safety prior to completion to support NDA resubmission review (filed 2026-05-07)
- Added statement that company is preparing to potentially resubmit NDA for ZYNQUISTA in type 1 diabetes if supported by patient exposure and safety data from such study (filed 2026-05-07)
- Added reference to 'PROGRESS Phase 2b clinical trial' and 'RELIEF-DPN-1 Phase 2a clinical trial' with specific naming (filed 2026-05-07)
- Added statement that company is 'currently advancing third party collaboration discussions' for pilavapadin development and commercialization (filed 2026-05-07)
- Added clarification that Novo Nordisk is 'currently conducting Phase 1 development' of LX9851 (filed 2026-05-07)
- Removed:
- Removed reference to pilavapadin alternative name '(LX 9211)' (filed 2025-11-06)
- Removed statement that company 'have completed three Phase 2 clinical trials' - changed to 'two Phase 2 clinical trials' (filed 2025-11-06)
- Removed reference to results from 'a separate Phase 2a clinical trial of pilavapadin in post-herpetic neuralgia' (filed 2025-11-06)
- Removed reference to company 'are conducting preclinical development of LX9851 in preparation for the filing of an investigational new drug application' (filed 2025-11-06)
- Removed statement that INPEFA is 'our orally-delivered small molecule drug' (filed 2025-11-06)
- Removed bullet point about sotagliflozin HCM development appearing as separate item in older version (filed 2025-11-06)
- Removed reference to 'an additional complete response letter in December 2024 regarding our NDA for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and CKD' (filed 2025-11-06)
- Reworded:
- Reorganized sotagliflozin HCM into first bullet point rather than separate paragraph (filed 2026-05-07)
- Changed 'three Phase 2 clinical trials' to 'two Phase 2 clinical trials' for pilavapadin (filed 2026-05-07)
- Reordered pilavapadin and LX9851 bullet points (pilavapadin moved before LX9851 in newer version) (filed 2026-05-07)
- Changed reference to complete response letters from 'an additional complete response letter in December 2024' to 'complete response letters regarding our New Drug Application' listing March 2019 and December 2024 separately (filed 2026-05-07)
- Reordered opening disclosure about sotagliflozin HCM to appear as first development program bullet (filed 2026-05-07)
- Reordered listing of drug program origins (filed 2026-05-07)
- Notes:
- Text truncated at 'Critical Accounting Policies' section in both versions, so comparison limited to Overview section
- Older filing section appears to have formatting issue with 'ev aluating' (spacing error in source text)
- Page numbering differs: older version shows '17' while newer shows '16', indicating possible layout changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LXRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LXRX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 79,152,319
- Reported value $189,965,565
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LXRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LXRX had 28,793,507 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
LXRX had 6.47% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.4 days to cover at the same settlement.
- Reported short interest (shares) 28,793,507
- Short interest (% of shares outstanding) 6.47%
- Prior settlement (shares) 29,490,809
- Reported change -2.36%
- Days to cover (reported) 13.4
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Eli Lilly (LLY)
- Sanofi (SNY)
- Boehringer Ingelheim
- Merck & Co. (MRK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LXRX vs…
LEXICON PHARMACEUTICALS INC is found in…
LXRX ranks in…
Frequently asked questions
What does LEXICON PHARMACEUTICALS INC (LXRX) do?
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drug candidates. The company utilizes a proprietary gene knockout technology to identify and validate targets for therapeutic intervention, primarily targeting areas of significant unmet medical need. Its business model relies on both direct commercialization of proprietary products and strategic licensing agreements.
What sector is LEXICON PHARMACEUTICALS INC (LXRX) in?
LEXICON PHARMACEUTICALS INC (LXRX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are LEXICON PHARMACEUTICALS INC's (LXRX) competitors?
Notable peers of LEXICON PHARMACEUTICALS INC (LXRX) include AstraZeneca, Eli Lilly, Sanofi, Boehringer Ingelheim and Merck & Co.. This peer set is informational only — not financial advice.
Is LEXICON PHARMACEUTICALS INC (LXRX) overbought or oversold right now?
LEXICON PHARMACEUTICALS INC (LXRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LXRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.